Skip to Content


Medically reviewed by Last updated on Sep 12, 2020.


(a bal oh PAR a tide)

Dosage Forms

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution Pen-injector, Subcutaneous:

Tymlos: 3120 mcg/1.56 mL (1.56 mL) [contains phenol]

Brand Names: U.S.

  • Tymlos

Pharmacologic Category

  • Parathyroid Hormone Analog


Abaloparatide is an analog of human parathyroid hormone related peptide (PTHrP[1-34]), which acts as an agonist at the PTH1 receptor (PTH1R). This results in stimulation of osteoblast function and increased bone mass (Harslof 2016; Leder 2017).


Vd: ~50 L


Hepatic (nonspecific proteolysis)


Urine (as peptide fragments)

Time to Peak

0.51 hours (range: 0.25 to 0.52 hours)

Half-Life Elimination

1.7 hours

Protein Binding


Special Populations: Renal Function Impairment

Maximum serum concentration increased 1-, 1.3- and 1.4-fold in patients with mild, moderate and severe renal impairment, respectively. AUC increased 1.2-, 1.7- and 2.1-fold in patients with mild, moderate and severe renal impairment, respectively.

Use: Labeled Indications

Osteoporosis: Treatment of postmenopausal females with osteoporosis at high risk for fracture (defined as a history of osteoporotic fracture or multiple risk factors for fracture). May also be used in patients who have failed or are intolerant to other available osteoporosis therapy.

Limitations of use: Cumulative lifetime duration of abaloparatide (and/or teriparatide) therapy should not exceed 2 years.


Hypersensitivity (eg, anaphylaxis, dyspnea, urticaria) to abaloparatide or any component of the formulation.

Dosing: Adult

Note: Patients should receive supplemental calcium and vitamin D if dietary intake is inadequate; however, use caution to avoid hypercalcemia. Assess serum calcium prior to initiation; avoid use in patients with preexisting hypercalcemia or hypercalcemic disorder.

Osteoporosis, treatment (postmenopausal females):

Note: Use may be considered for reduction of vertebral and nonvertebral fractures in patients with very high fracture risk, including those with a T-score less than –3, a T-score less than –2.5 with fracture history, multiple prior vertebral fractures, a fracture within prior 12 months, or a very high fracture risk according to a risk assessment tool; may also be used as an alternative agent in patients for whom first-line therapies are not tolerated or ineffective (AACE/ACE [Camacho 2020]; ES [Eastell 2019]).

SubQ: 80 mcg once daily.

Discontinuation/interruption of therapy: Because the benefits of anabolic therapy are quickly lost after discontinuation, it is generally recommended to initiate antiresorptive therapy (bisphosphonate or alternative) to maintain bone density gains following a course of abaloparatide (AACE/ACE [Camacho 2020]; Bone 2018; ES [Eastell 2019]).

Duration of therapy: Fracture reduction efficacy has been demonstrated over a period of 18 months. Cumulative lifetime duration of abaloparatide (and/or teriparatide) therapy should not exceed 2 years.

Dosing: Geriatric

Refer to adult dosing.


SubQ: Inject subcutaneously into the periumbilical region of the abdomen. Rotate the site of the injection every day and administer at approximately the same time every day. Do not administer intravenously or intramuscularly. Initial doses should occur under circumstances in which the patient may sit or lie down, in the event of orthostasis.

Dietary Considerations

Ensure adequate calcium and vitamin D intake; if dietary intake is inadequate, dietary supplementation is recommended. Females and males should consume:

Calcium: 1,000 mg/day (males: 50 to 70 years) or 1,200 mg/day (females ≥51 years and males ≥71 years) (IOM 2011; NOF [Cosman 2014]).

Vitamin D: 800 to 1,000 int. units/day (males and females ≥50 years) (NOF [Cosman 2014]). Recommended Dietary Allowance (RDA): 600 int. units/day (males and females ≤70 years) or 800 int. units/day (males and females ≥71 years) (IOM 2011).


Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze or heat. After first use, store for up to 30 days at 20°C to 25°C (68°F to 77°F).

Drug Interactions

There are no known significant interactions.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.


Endocrine & metabolic: Increased uric acid (25%)

Genitourinary: Hypercalciuria (11% to 20%)

Immunologic: Antibody development (49%; neutralizing antibodies: 68%; antibody formation was not found to have any clinical significance)

Local: Erythema at injection site (58%)

1% to 10%:

Cardiovascular: Palpitations (5%), orthostatic hypotension (1% to 4%), sinus tachycardia (≤2%), tachycardia (≤2%)

Central nervous system: Dizziness (10%), headache (8%), fatigue (3%)

Endocrine & metabolic: Hypercalcemia (3%)

Gastrointestinal: Nausea (8%), upper abdominal pain (3%)

Local: Swelling at injection site (10%), pain at injection site (9%)

ALERT: U.S. Boxed Warning


Abaloparatide caused a dose-dependent increase in the incidence of osteosarcoma, a malignant bone tumor, in male and female rats. The effect was observed at systemic exposures to abaloparatide ranging from 4 to 28 times the exposure in humans receiving the 80 mcg dose. It is unknown whether abaloparatide will cause osteosarcoma in humans.

Use of abaloparatide is not recommended in patients at increased risk for osteosarcoma including those with Paget's disease of bone or unexplained elevations of alkaline phosphatase, open epiphyses, bone metastases or skeletal malignancies, hereditary disorders predisposing to osteosarcoma, or prior external beam or implant radiation therapy involving the skeleton.

Cumulative use of abaloparatide and parathyroid hormone analogs (eg, teriparatide) for more than 2 years during a patient's lifetime is not recommended.


Concerns related to adverse effects:

• Hypercalcemia: May cause or exacerbate hypercalcemia; use is not recommended in patients with preexisting hypercalcemia or with an underlying hypercalcemic disorder (eg, primary hyperparathyroidism).

• Orthostatic hypotension: May cause orthostatic hypotension. Transient orthostatic hypotension usually occurs within 4 hours of dosing.

• Osteosarcoma: [US Boxed Warning]: In animal studies, abaloparatide has been associated with an increase in osteosarcoma; risk was dependent on both dose and duration. Avoid use in patients with an increased risk of osteosarcoma (including Paget disease, bone metastases or skeletal malignancies, hereditary disorders predisposing to osteosarcoma, unexplained elevation of alkaline phosphatase, prior external beam or implant radiation therapy involving the skeleton, or in patients with open epiphyses).

Disease-related concerns:

• Urolithiasis: Use may cause hypercalciuria; use with caution in patients with active or recent urolithiasis because of risk of exacerbation.

Other warnings/precautions:

• Appropriate use: [US Boxed Warning]: Use for >2 years during a patient's lifetime is not recommended.

Monitoring Parameters

Orthostatic hypotension; serum calcium; urinary calcium (patients with suspected active urolithiasis or preexisting hypercalciuria).

Bone mineral density (BMD) should be evaluated at baseline and ~1 to 2 years following initiation of therapy (AACE/ACE [Camacho 2020]; ES [Eastell 2019]; NOF [Cosman 2014]); may consider monitoring biochemical markers of bone turnover (eg, serum P1NP) at baseline, 3 months, and 6 months, to assess treatment response (ES [Eastell 2019]; Miller 2016).

Pregnancy Considerations

Abaloparatide is not indicated for use in women of reproductive potential. Animal reproduction studies have not been conducted.

Patient Education

What is this drug used for?

• It is used to put off soft, brittle bones (osteoporosis) in women after change of life.

• It may be given to you for other reasons. Talk with the doctor.

All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away:

• Nausea

• Headache

• Loss of strength and energy

• Abdominal pain

• Injection site irritation

WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:

• High calcium like weakness, confusion, fatigue, headache, nausea and vomiting, constipation, or bone pain.

• Kidney stone like back pain, abdominal pain, or blood in the urine.

• Bone pain

• Skin swelling

• Lump

• Persistent pain

• Severe dizziness

• Passing out

• Fast heartbeat

• Abnormal heartbeat

• Muscle weakness

• Painful urination

• Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.

Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.

Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a limited summary of general information about the medicine's uses from the patient education leaflet and is not intended to be comprehensive. This limited summary does NOT include all information available about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not intended to provide medical advice, diagnosis or treatment and does not replace information you receive from the healthcare provider. For a more detailed summary of information about the risks and benefits of using this medicine, please speak with your healthcare provider and review the entire patient education leaflet.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.